Arjun Agarwal Sells 533 Shares of Oruka Therapeutics (NASDAQ:ORKA) Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) SVP Arjun Agarwal sold 533 shares of Oruka Therapeutics stock in a transaction dated Monday, September 21st. The shares were sold at an average price of $95.75, for a total transaction of $51,034.75. Following the sale, the senior vice president owned 14,219 shares of the company’s stock, valued at $1,361,469.25. The trade was a 3.61% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Arjun Agarwal also recently made the following trade(s):

• On Tuesday, September 15th, Arjun Agarwal sold 560 shares of Oruka Therapeutics stock. The shares were sold at an average price of $95.71, for a total transaction of $53,597.60.
• On Friday, September 11th, Arjun Agarwal sold 9,459 shares of Oruka Therapeutics stock. The stock was sold at an average price of $92.23, for a total transaction of $872,403.57.
• On Thursday, August 13th, Arjun Agarwal sold 10,000 shares of Oruka Therapeutics stock. The stock was sold at an average price of $106.66, for a total transaction of $1,066,600.00.
• On Monday, July 13th, Arjun Agarwal sold 9,999 shares of Oruka Therapeutics stock. The shares were sold at an average price of $84.63, for a total transaction of $846,215.37.

Oruka Therapeutics Trading Down 1.7%

Shares of NASDAQ ORKA traded down $1.58 during trading hours on Monday, reaching $93.38. The stock had a trading volume of 1,185,411 shares, compared to its average volume of 1,098,345. The firm has a market cap of $6.18 billion, a price-to-earnings ratio of -46.00 and a beta of -0.34. The business’s fifty day moving average price is $96.40 and its two-hundred day moving average price is $74.07. Oruka Therapeutics, Inc. has a 52-week low of $14.89 and a 52-week high of $115.51.

Oruka Therapeutics (NASDAQ:ORKA) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.04). Equities research analysts anticipate that Oruka Therapeutics, Inc. will post -2.42 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

ORKA has been the subject of several recent research reports. Mizuho set a $120.00 price objective on Oruka Therapeutics in a report on Thursday, September 3rd. BTIG Research reissued a “buy” rating and set a $151.00 target price on shares of Oruka Therapeutics in a research report on Tuesday, August 11th. Guggenheim reissued a “buy” rating and set a $200.00 target price on shares of Oruka Therapeutics in a research report on Tuesday, August 11th. Piper Sandler restated an “overweight” rating and issued a $180.00 price target on shares of Oruka Therapeutics in a report on Tuesday, June 2nd. Finally, Wedbush reaffirmed an “outperform” rating and issued a $165.00 price target on shares of Oruka Therapeutics in a research report on Tuesday, August 11th. Ten research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Oruka Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $133.00.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the stock. BlackRock Inc. purchased a new stake in shares of Oruka Therapeutics during the 2nd quarter worth $474,916,000. Jupiter Topco LLC purchased a new position in Oruka Therapeutics in the second quarter valued at about $130,968,000. Bank of America Corp DE bought a new position in Oruka Therapeutics in the second quarter worth about $33,578,000. Braidwell LP bought a new position in Oruka Therapeutics in the second quarter worth about $26,473,000. Finally, Atika Capital Management LLC purchased a new stake in shares of Oruka Therapeutics during the first quarter valued at about $11,277,000. 56.44% of the stock is owned by institutional investors.

About Oruka Therapeutics

Oruka Therapeutics, Inc (NASDAQ:ORKA) is a clinical-stage biotechnology company developing long-acting monoclonal antibody therapies for immune-mediated diseases. The company’s research is focused on creating medicines that may allow less frequent dosing than existing biologic treatments.

Oruka’s initial development programs are aimed at inflammatory conditions, including psoriasis. Its pipeline includes engineered antibody candidates designed to target important immune pathways, including interleukin-23 and interleukin-17.